Ann: Best and Final Confirmation and Bridging Loan, page-229

Following on from my earlier post.

Within Australia based on the IER report and data from 2018/2019, the ResAppDx test could replace approximately 1.2M laboratory based tests annually.

Doing a bit of googling about the current pathology costs for respiratory screens based on the Medicare Benefits Schedule (MBS) I came across this for Covid 19 screening costs from July 2021. I couldn't find any info about the multiplex PCR respiratory assay which may be more closely aligned to what ResAppDx can check for.


Even assuming the lower end number of $50 for a COVID test and excluding other pathology based MBS items such as patient episode initiation fees and bulk-billing incentives (approx $10) the potential savings that ResAppDx could offer Medicare annually based on 1.2M tests are substantial.

Further googling turned up the following Australian Government Investment Fund.



Following a NO vote, this fund should be first port of call of the existing/ new board to spent some of their $9.3B cash on a great Aussie investment opportunity that not only offers excellent revenue associated with ResAppDx but also offers significant cost savings through Medicare.

Just my thoughts.